May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Immune Responses to Adeno Associated Virus Type2 Encoding Channelrhodopsin-2 in Genetically Blind Rat Model for Gene Therapy
Author Affiliations & Notes
  • E. Sugano
    Life science, Tohoku University International Advanced Research and Education Organization, Sendai, Japan
  • H. Tomita
    Biofunctional Science, Tohoku University Biomedical Engineering Research Organization, Sendai, Japan
  • H. Isago
    Biofunctional Science, Tohoku University Biomedical Engineering Research Organization, Sendai, Japan
  • H. Yawo
    Developmental Biology and Neuroscience, Tohoku University Graduate School of Life Sciences, Sendai, Japan
  • T. Ishizuka
    Developmental Biology and Neuroscience, Tohoku University Graduate School of Life Sciences, Sendai, Japan
  • M. Tamai
    Biofunctional Science, Tohoku University Biomedical Engineering Research Organization, Sendai, Japan
  • Footnotes
    Commercial Relationships  E. Sugano, None; H. Tomita, None; H. Isago, None; H. Yawo, None; T. Ishizuka, None; M. Tamai, None.
  • Footnotes
    Support  Japanese Retinitis Pigmentosa Society, Suzuken Memorial Foundation
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3008. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Sugano, H. Tomita, H. Isago, H. Yawo, T. Ishizuka, M. Tamai; Immune Responses to Adeno Associated Virus Type2 Encoding Channelrhodopsin-2 in Genetically Blind Rat Model for Gene Therapy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3008. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Our previous studies reported that the transduction of channelrhodopsin-2(ChR2) which is derived from Chlamydomonas to retinal ganglion cells (RGCs) restored visual response in aged dystrophic Royal College of Surgeons (RCS) rats. In this study, we investigated immunological responses against the vector and the transgene during the long-term transgene expression.

Methods: : Adeno-associated virus(AAV) vector encoding ChR2 gene was intravitreally injected into both eyes of RCS rats. Peripheral blood was collected pre- and post- the operation. Lymphocyte was separated by lysing blood cells and the number of leukocyte was counted. T cells were analyzed by a flowcytometer to assess the inflammation and the rejection. ChR2 protein expression in the retina was investigated by the observation of the fusion protein, venus in retinal whole mount specimen. Visually evoked potentials (VEPs) were recorded from visual cortex of the RCS rats by the flash of a blue light-emitting diode (LED).

Results: : After an year of ChR2 gene transfer, the ChR2 expression in retina and the recovered VEPs were investigated. There was no decrease of the protein expression and recorded amplitudes of VEPs. The number of leukocytes increased 2 weeks after the gene transfer. However, at one month of post-operation, the number of leukocytes was dropped to pre-operation level. As an inflammation maker, we investigated the ratio of CD4, CD8 and CD25 expression of T cells. There was no significant difference of the ratio during the experimental periods (1-year).

Conclusions: : rAAV2 vector administration to retina appears well tolerated. The increase of leukocytes might reveal some immune responses induced at the early stage of the AAV integration. But expression and function of ChR2 was not rejected by the host immune response mechanism during 1 year of observation. These data demonstrated that our approach, ChR2 transgene to retina with AAV vector, is reasonable for long-term gene therapy.

Keywords: gene transfer/gene therapy • regeneration • retinal degenerations: hereditary 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×